Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
6.57
-0.02 (-0.30%)
Aug 26, 2026, 12:58 PM EDT - Market open
Prelude Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 26.33 | 35.26 | 12.47 | 25.29 | 30.61 | 31.83 |
Short-Term Investments | 125.43 | 67.96 | 121.14 | 207.64 | 171.12 | 259.41 |
Cash & Short-Term Investments | 151.76 | 103.21 | 133.61 | 232.94 | 201.73 | 291.23 |
Cash Growth | 107.27% | -22.75% | -42.64% | 15.47% | -30.73% | 33.40% |
Prepaid Expenses | 3.14 | 2.48 | 2.28 | 2.65 | 2.65 | 3.88 |
Total Current Assets | 154.9 | 105.69 | 135.9 | 235.59 | 204.38 | 295.12 |
Property, Plant & Equipment | 30.79 | 32.28 | 35.47 | 37.74 | 6.7 | 5.64 |
Other Long-Term Assets | 3.68 | 3.35 | 4.15 | 4.34 | 9.42 | 4.35 |
Total Assets | 189.36 | 141.32 | 175.52 | 277.67 | 220.5 | 305.1 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.03 | 3.98 | 7.73 | 4.58 | 6.78 | 7.84 |
Accrued Expenses | 7.35 | 11.57 | 14.44 | 14.82 | 12.57 | 9.53 |
Current Portion of Leases | 2.78 | 2.74 | 2.7 | 1.48 | 1.83 | 1.74 |
Current Unearned Revenue | 25.25 | 33.73 | - | - | - | - |
Other Current Liabilities | 0.63 | 0.97 | 0.77 | 0.95 | 0.52 | 0.09 |
Total Current Liabilities | 38.04 | 52.99 | 25.64 | 21.83 | 21.7 | 19.2 |
Long-Term Leases | 14.87 | 15.05 | 15.33 | 15.41 | - | - |
Long-Term Unearned Revenue | - | 1.8 | - | - | - | - |
Other Long-Term Liabilities | 2.72 | 2.84 | 3.09 | 3.34 | 3.36 | - |
Total Liabilities | 55.63 | 72.68 | 44.06 | 40.58 | 25.06 | 19.2 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 841.32 | 751.68 | 714.98 | 693.25 | 531.68 | 505.72 |
Retained Earnings | -707.37 | -683.06 | -583.56 | -456.39 | -334.56 | -219.12 |
Comprehensive Income & Other | -0.23 | 0.01 | 0.04 | 0.22 | -1.69 | -0.71 |
Total Common Equity | 133.73 | 68.64 | 131.46 | 237.09 | 195.44 | 285.9 |
Shareholders' Equity | 133.73 | 68.64 | 131.46 | 237.09 | 195.44 | 285.9 |
Total Liabilities & Equity | 189.36 | 141.32 | 175.52 | 277.67 | 220.5 | 305.1 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 17.65 | 17.79 | 18.03 | 16.89 | 1.83 | 1.74 |
Net Cash (Debt) | 134.11 | 85.43 | 115.59 | 216.05 | 199.9 | 289.49 |
Net Cash Growth | 142.51% | -26.10% | -46.50% | 8.08% | -30.95% | 32.61% |
Net Cash Per Share | 1.59 | 1.11 | 1.52 | 3.58 | 4.22 | 6.29 |
Filing Date Shares Outstanding | 102.99 | 82.53 | 75.99 | 75.73 | 47.71 | 47.02 |
Total Common Shares Outstanding | 102.95 | 82.49 | 75.98 | 75.72 | 47.7 | 46.99 |
Working Capital | 116.86 | 52.7 | 110.25 | 213.76 | 182.68 | 275.91 |
Book Value Per Share | 1.30 | 0.83 | 1.73 | 3.13 | 4.10 | 6.08 |
Tangible Book Value | 133.73 | 68.64 | 131.46 | 237.09 | 195.44 | 285.9 |
Tangible Book Value Per Share | 1.30 | 0.83 | 1.73 | 3.13 | 4.10 | 6.08 |
Machinery | - | 10.34 | 10.33 | 8.97 | 5.72 | 4.38 |
Construction In Progress | - | - | - | 0.34 | 1.64 | 0.67 |
Leasehold Improvements | - | 1.71 | 1.7 | 1.58 | 0.88 | 0.88 |